10,569 results match your criteria Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors and their Appearance in Patients with Neurofibromatosis Type 1.

Radiographics 2022 May 20:220062. Epub 2022 May 20.

From the Department of Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia (A.N.M.); and Medical Research Institute of New Zealand, Wellington, New Zealand, and Artibiotics, Wellington, New Zealand (C.K.).

View Article and Full-Text PDF

[Gastrointestinal stromal tumors: potential of minimally invasive surgical interventions].

Khirurgiia (Mosk) 2022 (5):25-33

National Medical Research Centre for Oncology, Rostov-on-Don, Russia.

Objective: To analyze the issue of gastrointestinal stromal tumors (GISTs) and potential of minimally invasive surgical interventions.

Material And Methods: We analyzed postoperative outcomes in 97 patients with gastric and intestinal GISTs who underwent surgical treatment at the National Medical Research Centre for Oncology between 2015 and 2020.

Results: Twenty (24. Read More

View Article and Full-Text PDF
January 2022

Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.

Sci Rep 2022 May 18;12(1):8275. Epub 2022 May 18.

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Research Pavilion, Suite G.17, 5117 Centre Avenue, Pittsburgh, PA, 15213, USA.

Although KIT-mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib. Resistance mechanisms mainly involve secondary mutations in the KIT receptor tyrosine kinase gene indicating continued dependency on the KIT signaling pathway. The fact that the type of secondary mutation confers either sensitivity or resistance towards TKIs and the notion that secondary mutations exhibit intra- and intertumoral heterogeneity complicates the optimal choice of treatment in the imatinib-resistant setting. Read More

View Article and Full-Text PDF

Clinical Outcomes of Laparoscopic Proximal Gastrectomy With Double-Flap Reconstruction for Tumors in the Upper Third of the Stomach.

Surg Laparosc Endosc Percutan Tech 2022 Apr 22. Epub 2022 Apr 22.

Department of Medical Statistics and Informatics, Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.

Purpose: Laparoscopic proximal gastrectomy (LPG) has been a standard surgery for early gastric cancer in the upper third of the stomach and large esophagogastric junction gastrointestinal stromal tumor. However, how to reconstruct the stomach after LPG is still debated. This study aimed to evaluate the results of LPG with double-flap reconstruction. Read More

View Article and Full-Text PDF

Somatic pharmacogenomics of gastrointestinal stromal tumor.

Cancer Drug Resist 2019 19;2(1):107-115. Epub 2019 Mar 19.

Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.

Gastrointestinal stromal tumors (GISTs) are rare entities, which, however, represent the most common mesenchymal tumor of the gastrointestinal tract. The discovery of gain of function mutations on and receptor genes led to a deep revolution in the knowledge of this tumor. This paved the way to the introduction of imatinib and other tyrosine-kinase inhibitors (TKIs), which terrifically revolutionized the prognosis of GIST patients. Read More

View Article and Full-Text PDF

Useful histopathologic features for diagnosing focal liver lesions with spindle cell morphology: A clinicopathologic study.

Ann Diagn Pathol 2022 May 10;59:151975. Epub 2022 May 10.

Department of Pathology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Background: Focal liver lesions with spindle cell morphology are rare in the daily practice of pathology. The differential diagnosis is broad, including both tumors and tumor-like lesions. Initial radiologic assessment is sometimes inaccurate. Read More

View Article and Full-Text PDF

Liver transplantation for metastatic non-resectable gastrointestinal stromal tumor after molecular targeted therapies: A case report.

Int J Surg Case Rep 2022 May 11;95:107185. Epub 2022 May 11.

Department of Pathology, Xiang'an Hospital of Xiamen University, Xiamen 361000, China; Organ Transplantation Institute of Xiamen University, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen 361000, China. Electronic address:

Introduction And Importance: Metastatic GIST (gastrointestinal stromal tumor) is most commonly seen in the liver. Surgical resection and Imatinib administration are the preferred treatment for localized and potentially resectable GIST. However, it is still a matter of debate about the optimal therapeutic management for unresectable, liver-confined, metastatic GIST even after the administration of imatinib. Read More

View Article and Full-Text PDF

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor.

J Vis Exp 2022 May 2(183). Epub 2022 May 2.

Department of Surgery, Hospital of the University of Pennsylvania;

Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and is typically driven by a single mutation in the KIT receptor. Across tumor types, numerous mouse models have been developed in order to investigate the next generation of cancer therapies. However, in GIST, most in vivo studies use xenograft mouse models which have inherent limitations. Read More

View Article and Full-Text PDF

Solid Pseudopapillary Neoplasm of the Pancreas Presenting With Gastric Outlet Obstruction.

Cureus 2022 Apr 13;14(4):e24092. Epub 2022 Apr 13.

Gastroenterology, School of Digestive and Liver Diseases, Institute of Postgraduate Medical Education and Research, Kolkata, IND.

Solid pseudopapillary neoplasm (SPN) of the pancreas are rare tumors accounting for a minor portion of all exocrine pancreatic tumors. It usually occurs in young women. It has a very low malignant potential with a relatively indolent clinical course. Read More

View Article and Full-Text PDF

Inhibition of CCCTC Binding Factor-Programmed Cell Death Ligand 1 Axis Suppresses Emergence of Chemoresistance Induced by Gastric Cancer-Derived Mesenchymal Stem Cells.

Front Immunol 2022 27;13:884373. Epub 2022 Apr 27.

School of Medicine, Jiangsu University, Zhenjiang, China.

Background: Gastric cancer (GC) is the third leading cause of cancer-associated deaths worldwide. Stromal cells, especially mesenchymal stem cells (MSCs), play significant roles in the development of therapy resistance depending on their paracrine function. The PD-1/PD-L1 crosstalk between cancer and immune cells has been well studied. Read More

View Article and Full-Text PDF

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.

Int J Mol Sci 2022 Apr 23;23(9). Epub 2022 Apr 23.

Department of Hematology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.

KIT is a type-III receptor tyrosine kinase that contributes to cell signaling in various cells. Since KIT is activated by overexpression or mutation and plays an important role in the development of some cancers, such as gastrointestinal stromal tumors and mast cell disease, molecular therapies targeting mutations are being developed. In acute myeloid leukemia (AML), genome profiling via next-generation sequencing has shown that several genes that are mutated in patients with AML impact patients' prognosis. Read More

View Article and Full-Text PDF

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.

Clin Pharmacol Drug Dev 2022 May 13. Epub 2022 May 13.

Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, USA.

Ripretinib is a switch control KIT kinase inhibitor approved for treatment of adults with advanced gastrointestinal stromal tumors who received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib and its active metabolite (DP-5439) are cleared mainly via cytochrome P450 enzyme 3A4/5 (CYP3A4/5), and ripretinib solubility is pH-dependent, thus the drug-drug interaction potentials of ripretinib with itraconazole (strong CYP3A inhibitor), rifampin (strong CYP3A inducer), and pantoprazole (proton pump inhibitor) were each evaluated in open-label, fixed-sequence study designs. Overall, 20 participants received ripretinib 50 mg alone and with itraconazole 200 mg once daily, 24 participants received ripretinib 100 mg alone and with rifampin 600 mg once daily, and 25 participants received ripretinib 50 mg alone and with pantoprazole 40 mg once daily. Read More

View Article and Full-Text PDF

Value of F-FDG PET/CT for differentiating diagnosis between malignant and benign primary gastric gastrointestinal mesenchymal tumors: a single-center retrospective study.

J Gastrointest Oncol 2022 Apr;13(2):637-646

Department of Nuclear Medicine, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.

Background: Malignant primary gastric gastrointestinal stromal tumors (gGISTs) without treatment with imatinib are prone to bleeding and peritoneum implantation during operation. Therefore, preoperative assessment of the malignant potential of gGIST is essential. The use of F-fluorodeoxyglucose (F-FDG) positron emission tomography (PET) combined with computed tomography (PET/CT) as a non-invasive tool for diagnosis, staging and prognosis evaluation in oncology, may also be useful for gGISTs. Read More

View Article and Full-Text PDF

A Rare Case of the Coexistence of Pancreaticobiliary Maljunction and Gastrointestinal Tumor in Neurofibromatosis Type 1.

Cureus 2022 Apr 11;14(4):e24048. Epub 2022 Apr 11.

Gastroenterological Surgery, Osaka Saiseikai Noe Hospital, Osaka, JPN.

Neurofibromatosis type 1 (NF1) is a congenital condition characterized by "café au lait" spots and subcutaneous fibromas. There are various combined diseases, such as malignant tumors in the abdominal organs or brain tumors. Here, we present a case of a 35-year-old patient with a rare combination of NF1 with a gastrointestinal stromal tumor (GIST) and pancreaticobiliary maljunction (PBM). Read More

View Article and Full-Text PDF

Molecular Portrait of GISTs Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel.

Front Genet 2022 25;13:864499. Epub 2022 Apr 25.

Dian Diagnostics Group Co., Ltd., Hangzhou, China.

The study aims to investigate genetic characterization of molecular targets and clinicopathological features with gastrointestinal stromal tumors based on targeted next-generation sequencing. We selected 106 patients with GISTs from Sir Run Run Shaw Hospital between July 2019 and March 2021. FFPE samples and paired blood samples were obtained from these patients who underwent excision of the tumor. Read More

View Article and Full-Text PDF

An exploration in pitfalls in interpreting SDHB immunohistochemistry.

Histopathology 2022 May 11. Epub 2022 May 11.

Department of Pathology, University of California, San Francisco.

Aims: Mutations and epimutations in genes encoding the succinate dehydrogenase complex (SDHx) are associated with multiple tumor types in which identification of SDH-deficiency has significant management implications. Immunohistochemistry (IHC) for the SDHB subunit can help detect SDH-deficiency, which manifests as complete loss of staining in tumor cells. However, a subset of SDH-deficient tumors can show aberrant cytoplasmic SDHB-IHC staining patterns and be misinterpreted as "retained," a diagnostic pitfall complicating interpretation. Read More

View Article and Full-Text PDF

Catching the GIST: Massive Gastrointestinal Stromal Tumor Presenting as Acute Dyspnea.

J Radiol Case Rep 2022 Apr 1;16(4):11-16. Epub 2022 Apr 1.

Department of Critical Care, University of Houston/HCA Houston Healthcare Kingwood, TX, USA.

We present a case of a 55-year-old woman presenting with worsening shortness of breath and constipation over the course of three days. Initial computed tomography scan showed a large, complex abdominal mass with a vascular pedicle and possible pedunculated origin along the inferior aspect of the greater curvature of the stomach. The mass was further evaluated on magnetic resonance imaging showing an active hemorrhage. Read More

View Article and Full-Text PDF

Lower Extremity Varicose Veins: An Unusual Presentation of Small Bowel Leiomyosarcoma.

Gastrointest Tumors 2022 Mar 18;9(1):1-4. Epub 2021 Nov 18.

Internal Medicine, Advocate Aurora Health/Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA.

Leiomyosarcomas (LMSs) are extremely rare and comprise only 1.2% of small bowel malignancies. Advancements in immunohistochemical techniques have allowed for the differentiation between LMSs and gastrointestinal stromal tumors. Read More

View Article and Full-Text PDF

Tyrosine kinase inhibitors in sarcoma treatment.

Oncol Lett 2022 Jun 21;23(6):183. Epub 2022 Apr 21.

Second Propaedeutic Department of Medicine, Attikon University Hospital, 12462 Athens, Greece.

Sarcomas are a group of rare mesenchymal malignant tumors that arise from transformed cells of the mesenchymal connective tissue, which are challenging to treat. The majority of sarcomas are soft tissue sarcomas (STSs; 75%) and this heterogeneous group of tumors is further comprised of gastrointestinal stromal tumors (~15%) and bone sarcomas (10%). Although surgery remains the current primary therapeutic approach for localized disease, recurrent, metastatic and refractory sarcomas require cytotoxic chemotherapy, which usually yields poor results. Read More

View Article and Full-Text PDF

Ki67 for evaluating the prognosis of gastrointestinal stromal tumors: A systematic review and meta-analysis.

Oncol Lett 2022 Jun 27;23(6):189. Epub 2022 Apr 27.

Department of General Surgery, Chongqing Western Hospital, Chongqing 400051, P.R. China.

Overexpression of Ki67 is observed in tumor cells, and it has been suggested to be a marker for cancer prognosis. However, the relationship between Ki67 expression and the risk of recurrence of gastrointestinal stromal tumors (GISTs) remains poorly defined. In the present study, a meta-analysis was used to examine the associations between Ki67 levels and GIST recurrence. Read More

View Article and Full-Text PDF

Laparoscopic distal gastrectomy for synchronous adenocarcinoma, diffuse large B cell lymphoma and gastrointestinal stromal tumor in the stomach: a case report.

Surg Case Rep 2022 May 8;8(1):89. Epub 2022 May 8.

Second Department of Surgery, School of Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8510, Japan.

Background: Synchronous lymphoma and adenocarcinoma are occasionally detected in the stomach. Gastrointestinal stromal tumor (GIST) and adenocarcinoma are sometimes seen simultaneously in the stomach. However, we rarely observe synchronous adenocarcinoma, lymphoma, and GIST in the stomach, and there are few reports on cases with these three lesions. Read More

View Article and Full-Text PDF

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.

BMC Cancer 2022 May 6;22(1):511. Epub 2022 May 6.

Department of Medical Oncology, Leiden University, Leiden, The Netherlands.

Background: Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidylinositol 3-kinase inhibitor, used in combination with imatinib in patients with advanced GIST who had failed prior therapy with both imatinib and sunitinib.

Methods: This phase 1b, multicenter, open-label study consisted of 2 phases: dose escalation and dose expansion. Read More

View Article and Full-Text PDF

The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-15

Sarcoma Translational Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin and a compelling clinical and biologic model for the rational development of molecularly targeted agents. This is because the majority of GISTs are driven by gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinases. Specific GIST mutations circumscribe well-defined molecular subgroups that must be determined during the diagnostic work-up to guide clinical management, including therapeutic decisions. Read More

View Article and Full-Text PDF

Comparison of Prognosis Between Microscopically Positive and Negative Surgical Margins for Primary Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.

Front Oncol 2022 19;12:679115. Epub 2022 Apr 19.

Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: This meta-analysis aimed to determine the prognostic impact of microscopically positive margins (R1) on primary gastrointestinal stromal tumors.

Methods: A literature search was performed using PubMed, Embase, Web of Science, and Cochrane Library for studies up to 23 November 2020. The pooled disease-free survival (DFS) and overall survival (OS) between R1 and negative margins (R0) were estimated using a random-effects model. Read More

View Article and Full-Text PDF

[Gastrointestinal stromal tumor with right ventricle metastases: report of a case].

Zhonghua Bing Li Xue Za Zhi 2022 May;51(5):455-457

Department of Pathology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.

View Article and Full-Text PDF

Patient-derived micro-organospheres enable clinical precision oncology.

Cell Stem Cell 2022 Apr 27. Epub 2022 Apr 27.

Xilis, Inc., Durham, NC 27713, USA.

Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here, we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of micro-organospheres (MOSs) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. Read More

View Article and Full-Text PDF

Regorafenib induces the apoptosis of gastrointestinal cancer-associated fibroblasts by inhibiting AKT phosphorylation.

Stem Cells Dev 2022 May 2. Epub 2022 May 2.

Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Basic Medical Sciences, 196536, Centre of Excellence in Tissue Engineering,Chinese Academy of Medical Sciences , Beijing, Beijing, China.

Cancer-associated fibroblasts (CAFs) are a key component of tumor microenvironment and are essential for tumorigenesis and development. Regorafenib is a multikinase inhibitor that targets CAFs and suppresses tumor growth. Here, we investigated the effects of regorafenib on gastrointestinal CAFs and the underlying molecular mechanisms. Read More

View Article and Full-Text PDF

Efficacy and Safety of Endoscopic Resection for Small Gastric Gastrointestinal Stromal Tumors in Elderly Patients.

Gastroenterol Res Pract 2022 23;2022:8415913. Epub 2022 Apr 23.

Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou, Zhejiang Province, China 310003.

Background: Gastrointestinal stromal tumors (GISTs) are prevalent in elderly patients. Endoscopic resection has become popular for treating small (≤5 cm) gastric GISTs. However, little is known about the outcomes of endoscopic resection in elderly patients. Read More

View Article and Full-Text PDF